ZFAND6

Across TCGA pan-cancer cohorts, ZFAND6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZFAND6 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZFAND6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZFAND6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where ZFAND6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.861	0.401	.002	40	view →
CCRCC	DFS	Median	III,IV	0.809	1.000	.012	17	view →
LSCC	DFS	Tertile	All	1.000	0.446	.008	12	view →
HNSC	DFS	Quartile	All	0.267	0.860	.026	10	view →
UCEC	OS	Median	All	0.976	0.861	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZFAND6–LUAD (OS)

Open the LUAD breakdown →